Tesamorelin ���景与作用机制 — Research Overview

By Editorial Desk · published 2025-10-25 · last reviewed 2025-11-27 · News

The short version of TH9507 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-11-27. Anything still debated is marked as such rather than presented as settled.

tesamorelin 背景与作用机制

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

Tesamorelin Background and Mechanism

A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.

Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Related pages on this site

• Standard casebook
• Scalable casebook
• Verified notes
• Sustainable guide
• Gradual analysis
• Clear overview
• Optimized collection
• Measured summary

Identity and Development Background

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Profile

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Reference notes

== See also == History of atomic theory History of molecular theory History of crystallography before X-rays Geometrical crystallography before X-rays Physical crystallography before X-rays Timeline of chemistry Timeline of crystallography

== The role of specific tissues and organs in transamination == Transamination takes place in several tissues and organs, especially the liver and skeletal muscle, which work together to manage amino groups generated during amino acid catabolism. The liver is the primary site of transamination. After proteins are digested into their monomers, amino acids, these amino acids are transported to the liver. In the cytoplasm of hepatocytes, the amino groups from many amino acids are transferred to α-ketoglutarate, forming glutamate in a transamination reaction. Through this process the amino groups from different amino acids are combined into glutamate, reducing the need for multiple enzymes in subsequent elimination or biosynthetic processes. After this transamination reaction, glutamate is transported into the mitochondria, where glutamate dehydrogenase catalyzes an oxidative deamination reaction, releasing ammonium. Free ammonium is toxic to cells, so the liver rapidly converts it to carbamoyl phosphate through a reaction with bicarbonate, allowing it to enter the urea cycle for excretion. The liver also contains aspartate aminotransferase. This enzyme catalyzes a unique reaction where oxaloacetate, instead of α-ketoglutarate, serves as the amino-group acceptor. In this reaction, glutamate transfers an amino group to oxaloacetate, forming the amino acid aspartate and regenerating α-ketoglutarate. Aspartate can then enter the urea cycle, where it combines with citrulline. Skeletal muscles is another site of transamination.

== Preservation == Organic compounds originally in living organisms can be preserved in the rock record if certain requirements are met. Proper preservation requires ample supply of organic material, high burial of that organic matter, and that the organic matter is then polymerized and not degraded. The more degraded a biomolecule is the less specific of a biomarker it becomes, as multiple molecules may have the same hydrocarbon skeleton after diagenesis. However, polar terpenoids such as sugiol may be preserved in their unaltered forms in fossil conifers, potentially due to plant resins that protect them from degradation. In samples obtained from a Pliocene fossilized forest most molecules had been significantly degraded, but phenolic abietanes including sugiol remained intact and identifiable. Even in samples that had been approximately 37.7% decomposed as determined by comparing cellulose content, trace amounts of sugiol and more than 10% ferruginol were detected via GC/MS. Sugiol will remain detectable in a sample long after it has lost its anatomical identifiers, making it extremely useful in identifying extremely old or decomposed plant fossils. In a study of preserved fossil wood and buried samples from a middle Jurassic forest located in Poland, a negative correlation was observed between the preservation of anatomical features of the plant samples versus the chemical features.

== Commercial success == Lemonhead candies have been commercially successful since their inception. Lemonheads and other sour candy can also be attributed an increase in growth in non-chocolate confectioners’ sales as opposed to chocolate companies’ sales in the 2015 fiscal year. CEO of Ferrara Candy, Todd Siwak, said, “We are seeing a desire in Millennials for cherry gummy candy, especially with sour, sweet, and intense flavors”.

== External links == Software for calculating SPINA-GR and other parameters for endotyping glucose homeostasis. (Permanent DOI), (General information and US mirror) Functions for R and S for calculating SPINA-GBeta, SPINA-GR and SPINA-DI. (Permanent DOI) Package "SPINA" for the statistical environment R

Sources: en.wikipedia.org

Notes from published material

Ben Howlett (born 21 October 1988) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Howlett was selected by Essendon with pick 30 in the 2010 rookie draft, as a 21-year-old from Peel Thunder in the West Australian Football League. His final season with Peel Thunder saw him claim the club's best and fairest award. He was promoted to Essendon's senior list in the 2010 season. Howlett, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for one season which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. Howlett was delisted at the conclusion of the 2017 AFL season. He returned home to WA and signed with the club he was originally drafted from, Peel Thunder in the WAFL, for the 2018 season. In 2019, Howlett was named captain of the club, taking over from dual premiership captain Gerald Ugle. In Round 9 of the 2021 WAFL season Howlett played his 100th game for Peel Thunder against Swan Districts before announcing his retirement from WAFL footy at the end of that season.

=== ThermoFluor of membrane proteins === Membrane proteins are often isolated in the presence of hydrophobic solubilizing agents that can partition hydrophobic-binding dyes like 1,8-ANS and SYPRO orange and generate a fluorescence background that obscures observation of a Thermofluor protein melting signal. Nevertheless, careful optimization of conditions (e.g., to avoid micelle formation of the solubilizing agent) can often produce satisfactory assay conditions

The CONGEN program, as it became known, was developed largely by computational chemists Ray Carhart, Jim Nourse, and Dennis Smith. It was useful to chemists as a stand-alone program to generate chemical graphs showing a complete list of structures that satisfy the constraints specified by a user.

=== Pharmacokinetics === Little formal knowledge exists on 5-MAPB. It does not form the α-methyldopamine metabolite that contributes to the neurotoxicity of MDMA or MDA. A study in rats indicated that the major metabolites of 5-MAPB are 5-APB and 3-carboxymethyl-4-hydroxymethamphetamine.

Sources: en.wikipedia.org

Frequently asked questions